Journal of International Oncology››2016,Vol. 43››Issue (2): 113-.
Previous ArticlesNext Articles
GAO Jun-Rong, ZHANG Ti, CAO Man-Qing, ZHANG Xue-Jun, ZHU Xiao-Lin
Online:
2016-02-08Published:
2015-12-28GAO Jun-Rong, ZHANG Ti, CAO Man-Qing, ZHANG Xue-Jun, ZHU Xiao-Lin. Anticancer effect of metformin and regulation on HIF-1α[J]. Journal of International Oncology, 2016, 43(2): 113-.
[1] Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?[J]. Oncologist, 2004, 9Suppl 5: 3140. DOI:10.1634/theoncologist.99000531. [2] Ben Sahra I, Le MarchandBrustel Y, Tanti JF. Metformin in cancer therapy: a new perspective for an old antidiabetic drug?[J]. Mol Cancer Ther, 2010, 9(5): 10921099. DOI: 10.1158/15357163.MCT091186. [3] Bonini MG, Gantner BN. The multifaceted activities of AMPK in tumor progressionwhy the "one size fits all" definition does not fit at all?[J]. IUBMB Life, 2013, 65(11): 889896. DOI:10.1002/iub.1213. [4] Shi WY, Xiao D, Wang L, et al. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy[J]. Cell Death Dis, 2012, 3(3): e275. DOI:10.1038/cddis.2012.13. [5] Saito T, Chiba T, Yuki K, et al. Metformin, a diabetes drug, eliminates tumorinitiating hepatocellular carcinoma cells[J]. PLoS One, 2013, 8(7): e70010. DOI:10.1371/journal.pone.0070010. [6] Song CW, Lee H, Dings RP, et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells[J]. Sci Rep, 2012, 2: 362. DOI:10.1038/srep00362. [7] Queiroz EA, Puukila S, Eichler R, et al. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF7 breast cancer cells[J]. PLoS One, 2014, 9(5): e98207. DOI:10.1371/journal.pone.0098207. [8] Liang J, Shao SH, Xu ZX, et al. The energy sensing LKB1AMPK pathway regulates p27(kip1)phosphorylation mediating the decision to enter autophagy or apoptosis[J]. Nat Cell Biol, 2007, 9(2): 218224. [9] Short JD, Houston KD, Dere R, et al. AMPactivated protein kinase signaling results in cytoplasmic sequestration of p27[J]. Cancer Res, 2008, 68(16): 64966506. DOI:10.1158/00085472.CAN075756. [10] Samani AA, Yakar S, Leroith D, et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights[J]. Endocr Rev, 2007, 28(1): 2047. DOI:10.1210/er.20060001. [11] Scotlandi K, Picci P. Targeting insulinlike growth factor 1 receptor in sarcomas[J]. Curr Opin Oncol, 2008, 20(4): 419427. DOI:10.1097/CCO.0b013e328302edab. [12] Garofalo C, Capristo M, Manara MC, et al. Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug[J]. PLoS One, 2013, 8(12): e83832. DOI:10.1371/journal.pone.0083832. [13] Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning[J]. Cancer Discov, 2012, 2(9): 778790. DOI:10.1158/21598290.CD120263. [14] Rocha GZ, Dias MM, Ropelle ER, et al. Metformin amplifies chemotherapyinduced AMPK activation and antitumoral growth[J]. Clin Cancer Res, 2011, 17(12): 39934005. DOI:10.1158/10780432.CCR102243. [15] Zannella VE, Dal Pra A, Muaddi H, et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response[J]. Clin Cancer Res, 2013, 19(24): 67416750. DOI:10.1158/10780432.CCR131787. [16] Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission[J]. Cancer Res, 2009, 69(19): 75077511. DOI:10.1158/00085472.CAN092994. [17] Blandino G, Valerio M, Cioce M, et al. Metformin elicits anticancer effects through the sequential modulation of DICER and cMYC[J]. Nat Commun, 2012, 3: 865. DOI:10.1038/ncomms1859. [18] Takiyama Y, Harumi T, Watanabe J, et al. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF1α expression and Oxygen metabolism[J]. Diabetes, 2011, 60(3): 981992. DOI:10.2337/db100655. [19] Ece H, Cigdem E, Yuksel K, et al. Use of oral antidiabetic drugs (metformin and pioglitazone) in diabetic patients with breast cancer: how does it effect serum Hif1 alpha and 8Ohdg levels?[J]. Asian Pac J Cancer Prev, 2012, 13(10): 51435148. [20] Krymskaya VP, Snow J, Cesarone G, et al. mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia[J]. FASEB J, 2011, 25(6): 19221933. DOI:10.1096/fj.10175018. [21] Ranasinghe WK, Sengupta S, Williams S, et al. The effects of nonspecific HIF1α inhibitors on development of castrate resistance and metastases in prostate cancer[J]. Cancer Med, 2014, 3(2): 245251. DOI:10.1002/cam4.189. [22] Ling S, Feng T, Ke Q, et al. Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines[J]. Oncol Rep, 2014, 31(6): 26112618. DOI:10.3892/or.2014.3151. [23] Sheng B, Liu J, Li GH. Metformin preconditioning protects Daphnia pulex from lethal hypoxic insult involving AMPK, HIF and mTOR signaling[J]. Comp Biochem Physiol B Biochem Mol Biol, 2012, 163(1): 5158. DOI:10.1016/j.cbpb.2012.04.009. |
[1] | Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[4] | Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p, H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349. |
[5] | Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353. |
[6] | Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358. |
[7] | Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363. |
[8] | Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369. |
[9] | Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375. |
[10] | Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381. |
[11] | Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273. |
[12] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[13] | Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285. |
[14] | Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291. |
[15] | Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||